As previously reported, Credit Suisse analyst Saul Hadassin downgraded ResMed to Neutral from Outperform following the company's Q4 in line earnings. The analyst also lowered his price target on the shares to A$9.40 from A$9.70.

Reports Q3 revenue $1.2B, consensus $1.17B. "ResMed's strong third-quarter fiscal year 2024 results reflect robust patient and customer demand for our products and software solutions, leading to double-digit mask and accessories revenue growth along with ongoing operational efficiencies to drive margin improvement and increased profitability, resulting in double-digit growth in both operating profit and earnings per share," said Mick Farrell, ResMed's Chairman & CEO. "Over 2 billion people worldwide can benefit from a ResMed solution to help them sleep better, breathe better, and receive best-in-class healthcare right where they live. We remain laser-focused on bringing market-leading innovation to customers, including our latest AirCurve11 range of non-invasive ventilators and our recently launched AirFit F40 mask system, combined with our entire portfolio of products, software, and solutions, allowing us to continue to deliver value for all our stakeholders."